Cancer

Silicogenix Partners with BioDuro to Accelerate Novel Drug Discovery for Complex Diseases

Streamlining the Path from Concept to Preclinical Development for the Biopharmaceutical Industry PALO ALTO, Calif., June 10, 2025 /PRNewswire/ --…

7 months ago

Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation

CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today…

7 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today…

7 months ago

Southwest General Partners with Notable to Close Care Gaps and Redefine Patient Access

The health center will leverage Notable's AI Platform to automate highly manual processes, including registration, intake, and care gap outreach…

7 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98%BERKELEY, Calif. and MAINZ, Germany,…

7 months ago

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3…

7 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating,…

7 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive…

7 months ago

Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device…

7 months ago

Izotropic Revises License Agreement with The Regents of the University of California

- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) -- Amendment aligns with Company's timelines for IzoView…

7 months ago